M K Freynhofer

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi Biomarkers in acute coronary artery disease
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, 1160 Vienna, Austria
    Wien Med Wochenschr 162:489-98. 2012
  2. ncbi The role of platelets in athero-thrombotic events
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A 1160, Vienna, Austria
    Curr Pharm Des 18:5197-214. 2012
  3. ncbi Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?
    Matthias K Freynhofer
    3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
    Thromb Haemost 107:538-44. 2012
  4. ncbi Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria
    Thromb Haemost 105:435-43. 2011
  5. ncbi Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A 1160, Vienna, Austria
    Thromb Haemost 106:230-9. 2011

Detail Information

Publications5

  1. ncbi Biomarkers in acute coronary artery disease
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, 1160 Vienna, Austria
    Wien Med Wochenschr 162:489-98. 2012
    ..Finally, platelets are an old, yet rediscovered biomarker for ischemic cardiovascular outcomes that might be used to estimate the individual bleeding or thrombotic risk and to tailor antiplatelet therapy...
  2. ncbi The role of platelets in athero-thrombotic events
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A 1160, Vienna, Austria
    Curr Pharm Des 18:5197-214. 2012
    ....
  3. ncbi Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?
    Matthias K Freynhofer
    3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
    Thromb Haemost 107:538-44. 2012
    ..Tolerably stable results were obtained for the PRI from the median FI...
  4. ncbi Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria
    Thromb Haemost 105:435-43. 2011
    ..Since ADAMTS13 plasma concentration and the vWF/ADAMTS13-ratio are independently associated with rhythm stability, these indexes might be used for prediction of recurrence of AF...
  5. ncbi Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A 1160, Vienna, Austria
    Thromb Haemost 106:230-9. 2011
    ..With regard to differing cut-offs, exact standardisation of the VASP-P assay is mandatory. The use of GP-IIb/IIIa-blockers prevents MEA testing and limits its usability in unselected patients...